Stocksigma LogoStocksigma Logo

Wanbury Q2 FY27 Results: Operational Recovery and Regulatory Pipeline Expansion

Wanbury reported standalone Q2 FY27 revenue of Rs 182.9 crore, up 14.3% YoY and 10.5% QoQ, driven by recovery from previous West Asia supply disruptions

Wanbury Q2 FY27 Results: Operational Recovery and Regulatory Pipeline Expansion

Wanbury Ltd 路 Press Release 路 06 Nov 2026, 7:02 pm

Wanbury Q2 FY27 Results: Operational Recovery and Regulatory Pipeline Expansion Wanbury reported standalone Q2 FY27 revenue of Rs 182.9 crore, up 14.3% YoY and 10.5% QoQ, driven by recovery from previous West Asia supply disruptions. EBITDA rose 57.9% QoQ to Rs 26.2 crore with margins expanding 431 bps QoQ to 14.3%, while PAT reached Rs 11.9 crore. Lower borrowing rates reduced finance costs to Rs 6.3 crore. Operationally, the Tanuku facility received Australia鈥檚 TGA GMP certification on 28th Oct'26, EDQM approved Rivaroxaban API, and USFDA issued multiple "No DMF Deficiency" letters.

Original exchange filing (PDF)

More announcements from Wanbury Ltd

All Wanbury Ltd announcements